NRG Oncology/GOG Studies
- Chemo-radiation (chemoRT) has improved the overall survival for locally advanced cervical cancer (LACC) though women whose disease involves the para-aortic nodes (PAN) experience recurrence rates and worse survival outcomes compared to those without PAN involvement. This Phase I study determined if additional cycles of systemic chemotherapy could be safely added to extended field chemoRT in this population of patients.
- To evaluate the efficacy and tolerability of cabozantinib in recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer.
- Ovarian tumors are classified into three categories based on progenitor cell type: surface-epithelial, sex cord-stromal and germ cell neoplasms . Of these, epithelial ovarian cancers (EOCs which may, in fact, often originate from the fallopian tube) comprise the majority of cases, and these are usually diagnosed at an advanced stage with an associated poor prognosis. Serous epithelial ovarian carcinoma (SOC) is the most commonly observed subtype of EOC both in the United States  and worldwide [3,4].
A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group studyAdvanced epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy. Despite advances in surgical cytoreduction and chemotherapy, the five-year survival remains approximately 45.6% . Due to EOC being an immunogenic tumor, there has been significant interest in developing immunotherapy strategies using cytokines, monoclonal antibodies, checkpoint inhibitors, immune modulators, therapeutic vaccines, adoptive T cell transfer and oncolytic viruses.
- Intraperitoneal (IP) therapy improves survival compared to intravenous (IV) treatment for women with newly diagnosed, optimally cytoreduced, ovarian cancer. However, the role of IP therapy in recurrent disease is unknown. Preclinical data demonstrated IP administration of the proteasome inhibitor, bortezomib prior to IP carboplatin increased tumor platinum accumulation resulting in synergistic cytotoxicity. We conducted this phase I trial of IP bortezomib and carboplatin in women with recurrent disease.
- To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of veliparib combined with PLD and carboplatin (CD) in patients with recurrent, platinum-sensitive epithelial ovarian cancer. To determine the tolerability at the MTD combined with bevacizumab.
- Racial genetic admixture (RGA), a measure to account for ancestral genetic background that correlates with individual's racial classification, could provide insights on causation of racial disparity in endometrial cancer (EC). Our objective is to evaluate the association of RGA with EC outcomes.